From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.03
First Reported 2008
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 1
Disease Relevance 0.99
Pain Relevance 0.05

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (TXK, KDR) nucleus (TXK, KDR) cytoplasm (TXK, KDR)
extracellular region (KDR) cytoplasmic membrane-bounded vesicle (KDR) DNA binding (TXK)
TXK (Homo sapiens)
KDR (Homo sapiens)
Pain Link Frequency Relevance Heat
headache 4 50.96 Quite High
antagonist 1 48.88 Quite Low
Inflammation 5 5.00 Very Low Very Low Very Low
peripheral neuropathy 2 5.00 Very Low Very Low Very Low
Pain 2 5.00 Very Low Very Low Very Low
tolerance 1 5.00 Very Low Very Low Very Low
Potency 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Breast Cancer 59 98.56 Very High Very High Very High
Lung Cancer 1 94.96 High High
Advanced Or Metastatic Breast Cancer 84 86.80 High High
Lymphatic System Cancer 1 68.16 Quite High
Toxicity 14 53.84 Quite High
Headache 4 50.96 Quite High
Vomiting 13 50.56 Quite High
Diarrhoea 14 50.24 Quite High
Cancer 35 47.84 Quite Low
Disease 22 45.88 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Motesanib is a small molecule tyrosine kinase inhibitor of VEGF that targets VEGFR 1, 2, 3 and PDGF that has been evaluated in preclinical models in combination with either tamoxifen or docetaxel and was shown to have potential use in breast cancer.[68] A large phase II clinical trial is ongoing evaluating motesanib and paclitaxel in the treatment of breast cancer).[47]
Negative_regulation (inhibitor) of molecule tyrosine kinase Positive_regulation (targets) of VEGFR associated with breast cancer
1) Confidence 0.03 Published 2008 Journal J Hematol Oncol Section Body Doc Link PMC2579406 Disease Relevance 0.99 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools